STOCK TITAN

Tempest Therapeutics Inc - TPST STOCK NEWS

Welcome to our dedicated news page for Tempest Therapeutics (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tempest Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tempest Therapeutics's position in the market.

Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) presented promising preclinical data at the AACR Annual Meeting showcasing the efficacy of TPST-1120 in reducing kidney cancer growth. The data revealed a significant reduction in tumor growth as a monotherapy and enhanced inhibition when combined with frontline chemotherapy and immunotherapy. These findings support the positive clinical outcomes observed in previous studies, indicating the potential of TPST-1120 to transform the tumor microenvironment and enhance anti-tumor immunity in kidney cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
-
Rhea-AI Summary
Tempest Therapeutics, Inc. announces positive clinical data for TPST-1120, a PPAR⍺ antagonist, showing clinical activity in PD-1 inhibitor refractory and immune compromised cancers. The Company plans to move TPST-1120 into a Phase 3 trial in HCC after successful Phase 1 and Phase 1b/2 trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.2%
Tags
-
Rhea-AI Summary
Tempest Therapeutics, Inc. (TPST) reported positive randomized first-line HCC data for TPST-1120 combination therapy, new biomarker data, and plans for Phase 3 trials. Financially, Tempest ended 2023 with $39.2 million in cash, showing improved net loss and reduced expenses compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
Rhea-AI Summary
Tempest Therapeutics, Inc. presents promising preclinical data at SITC 2024 Spring Scientific Meeting for TPST-1120, a selective PPAR⍺ antagonist showing potent anti-tumor activity in various cancer models. Positive Phase 1 and 2 results support late-stage clinical development in liver cancer patients, with plans for pivotal study. Data indicates inhibition of PPAR⍺ as an effective cancer treatment strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics (TPST) collaborates with BIDMC to present preclinical data on TPST-1120 for renal cell carcinoma at AACR Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.09%
Tags
conferences clinical trial
-
Rhea-AI Summary
Tempest Therapeutics, Inc. (TPST) to present at the 44th Annual TD Cowen Healthcare Conference on March 4, 2024, focusing on cancer therapeutics development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.54%
Tags
conferences
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) has granted two employees nonqualified stock options to purchase 45,500 shares of its common stock under the Company’s 2023 Inducement Plan. The stock options will vest over a four-year period, with 25% of each of the options vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) announced the grant of a nonqualified stock option to purchase 4,500 shares of its common stock to an employee under the Company’s 2023 Inducement Plan. The option will vest over a four-year period, with 25% vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) granted one employee a nonqualified stock option to purchase 7,650 shares of its common stock under the Company’s 2023 Inducement Plan. The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of the employee’s start date, and 1/48th of the total shares vesting monthly thereafter, subject to continued employment on each vesting date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Tempest Therapeutics, Inc. (Nasdaq: TPST) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference. The company is a clinical-stage oncology company focusing on first-in-class therapeutics combining targeted and immune-mediated mechanisms. Management will be part of the discussion on November 28, 2023, at 3:00 p.m. ET. The live or archived recording can be accessed on the Tempest website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.25%
Tags
conferences
Tempest Therapeutics Inc

Nasdaq:TPST

TPST Rankings

TPST Stock Data

79.67M
17.77M
3.16%
29.33%
4.37%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Ann Arbor

About TPST

tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.